Please assess the completion status of the following clinical trial:

Trial Title: SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Body Mass index ≥ 27 kg/m2~* Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g~* eGFR ≥ 25 ml/min/1.73m2~* Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3 months prior to enrolment~* Signed Informed Consent~Exclusion Criteria:~* Diagnosis with type 1 or type 2 Diabetes~* Hba1c ≥ 6.5% at screening~* Cardiovascular disease event in 3 months prior to enrollment~* Treatment with GLP-1 RA \< 4 weeks prior to screening~* Uncontrolled thyroid disease TSH\>6.0 mIU/L or \<0.4 mIU/L at screening~* Acute pancreatitis \< 180 days prior to screening~* History or presence of chronic pancreatitis~* Females of child-bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a matching placebo s.c. once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).